Sign in to view content

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results

Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD
Annual Meeting Talks
2022
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more